Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review

INTRODUCTION: In 2016, SB4 (Benepali(®)) became the first etanercept (ETN) biosimilar to obtain marketing authorisation in Europe. Despite robust analytical and clinical comparisons, outstanding questions remain on SB4 use in routine practice. METHODS: A systematic search for publications on real-wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebbers, Hans C., Pieper, Burkhard, Issa, Amine, Addison, Janet, Freudensprung, Ulrich, Rezk, Mourad F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702587/
https://www.ncbi.nlm.nih.gov/pubmed/31385263
http://dx.doi.org/10.1007/s40744-019-00169-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702587/
https://www.ncbi.nlm.nih.gov/pubmed/31385263
http://dx.doi.org/10.1007/s40744-019-00169-4

Ejemplares similares